AbCellera Biologics Inc. Income Statement
ABCL / Health Care|7 years of annual SEC 10-K data (FY2019-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
AbCellera Biologics Inc. reported $75M in revenue and $146M in net loss for FY2025. Revenue has grown at a 36.5% compound annual rate over the past 6 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.93 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $75.1M | $28.8M | $38.0M | $485.4M | $11.6M | $233.2M | $11.6M |
| SG&A Expense | $83.2M | $85.5M | $75.2M | $55.5M | $2.7M | $11.9M | $2.7M |
| R&D Expense | $186.8M | $167.3M | $175.7M | $107.9M | $10.1M | $29.4M | $10.1M |
| Operating Income | -$217.1M | -$314.8M | -$237.2M | $216.5M | -$4.1M | $156.0M | -$4.1M |
| Income Tax | -$31.2M | -$37.5M | -$27.6M | $80.6M | $38.9M | $38.9M | - |
| Net Income | -$146.4M | -$162.9M | -$146.4M | $158.5M | -$2.2M | $118.9M | -$2.2M |
| EPS (Basic) | -$0.49 | -$0.55 | -$0.51 | $0.56 | -$0.01 | $0.53 | -$0.01 |
| EPS (Diluted) | -$0.49 | -$0.55 | -$0.51 | $0.50 | -$0.01 | $0.45 | -$0.01 |
| Shares Outstanding | 300.6M | 295.8M | 290.8M | 286.9M | 269.5M | 263.1M | 151.3M |
| Operating Margin | -289.0% | -1091.7% | -623.8% | 44.6% | -35.4% | 66.9% | -35.5% |
| Profit Margin | -194.9% | -564.8% | -385.0% | 32.7% | -19.0% | - | -19.0% |